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Background: Several studies have revealed a potential role for both small nucleolar RNAs (snoRNAs) and microRNAs
(miRNAs) in the physiopathology of relapsing-remitting multiple sclerosis (RRMS). This potential implication has been
mainly described through differential expression studies. However, it has been suggested that, in order to extract
additional information from large-scale expression experiments, differential expression studies must be complemented
with differential network studies. Thus, the present work is aimed at the identification of potential therapeutic ncRNA
targets for RRMS through differential network analysis of ncRNA – mRNA coexpression networks. ncRNA – mRNA
coexpression networks have been constructed from both selected ncRNA (specifically miRNAs, snoRNAs and sdRNAs)
and mRNA large-scale expression data obtained from 22 patients in relapse, the same 22 patients in remission and 22
healthy controls. Condition-specific (relapse, remission and healthy) networks have been built and compared to identify
the parts of the system most affected by perturbation and aid the identification of potential therapeutic targets among
the ncRNAs.
Results: All the coexpression networks we built present a scale-free topology and many snoRNAs are shown to have a
prominent role in their architecture. The differential network analysis (relapse vs. remission vs. controls’ networks) has
revealed that, although both network topology and the majority of the genes are maintained, few ncRNA – mRNA links
appear in more than one network. We have selected as potential therapeutic targets the ncRNAs that appear in the
disease-specific network and were found to be differentially expressed in a previous study.
Conclusions: Our results suggest that the diseased state of RRMS has a strong impact on the ncRNA – mRNA network
of peripheral blood leukocytes, as a massive rewiring of the network happens between conditions. Our findings also
indicate that the role snoRNAs have in targeted gene silencing is a widespread phenomenon. Finally, among the
potential therapeutic target ncRNAs, SNORA40 seems to be the most promising candidate.
Keywords: Multiple sclerosis, ncRNA, snoRNA, miRNA, Coexpression, Differential network, Therapeutic target,
Rewiring, ACA40* Correspondence: david.otaegui@biodonostia.org
1Multiple Sclerosis group, Biodonostia Health Research Institute, Paseo Dr.
Begiristain s/n, San Sebastián 20001, Spain
2Spanish Network on Multiple Sclerosis (REEM), San Sebastián, Spain
Full list of author information is available at the end of the article
© 2015 Irizar et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Irizar et al. BMC Genomics  (2015) 16:250 Page 2 of 15Background
The huge development of molecular biology in the last
few decades has allowed us to observe how, as we have
gained insight into the biology of the cell, the regulation
of gene expression has revealed more and more com-
plexity around the central DNA→RNA→ protein axis
that provides the backbone to our view of molecular
biology. Additional levels of regulation and new players
have appeared with substantial roles on the regulation of
the expression of our genes. During the last decade, it
has become evident that small non-coding RNAs
(sncRNAs) participate in widespread and essential re-
gulatory mechanisms in most eukaryotic cells. Novel
classes of small RNAs, their biogenesis pathways and
cellular effects are continuously being described, and
new properties of already established sncRNAs are still
being discovered [1]. A broad range of sncRNA types
have already been characterized (microRNAs, siRNAs,
piRNAs etc.) [1,2] but, among them, the microRNAs
(miRNAs) have occupied an indisputable central pos-
ition since their characterization as a distinct class of
biological regulators with conserved functions in the
early 2000s [3-5].
MicroRNAs regulate gene expression at the post-
transcriptional level and have been shown to be involved
in almost all biological processes like development, cell
differentiation, proliferation and cell death and also in
several pathological events like cancer, neurodegenera-
tion or autoimmunity [6-9]. Among other autoimmune
diseases, alterations in miRNAs have been related to
multiple sclerosis (MS), as in the last years several works
have studied miRNA expression in a variety of tissues
(peripheral blood, brain and CSF) from MS patients and
in the Experimental Autoimmune Encephalitis (EAE)
animal model (reviewed in [10]). All these studies found
alterations in miRNA expression levels in MS patients
compared to healthy controls and therefore, an implica-
tion for miRNAs seems to be evident. Yet, little overlap
is observed among different studies, probably due to the
difference in the miRNA profiling technology, the com-
plexity of the tissue being studied and the relatively
small sample size of all studies.
In addition to the miRNAs, the small nucleolar RNAs
(snoRNAs) have also been shown to have important
functions in cell homeostasis. snoRNAs are 60 to 300
nucleotide-long ncRNAs that are generally required for
alternative splicing and RNA modifications. Two main
types of snoRNAs have been described, the box C/D
snoRNAs (SNORDs), implicated in the guidance of
2’o-ribose-methylation of ribosomal RNA (rRNA), and
the box H/ACA snoRNAs (SNORAs) that guide pseu-
douridylation of target rRNAs. Although it was thought
that snoRNAs were involved only in alternative splicing
and rRNA modification, a good amount of evidenceindicates that they can exert their gene expression regu-
latory effect by specifically targeting other RNAs, such
as small-nuclear RNAs (snRNAs) and mRNAs, thanks to
their capacity to function as precursors of the so called
snoRNA-derived RNAs (sdRNAs) [11]. As for micro-
RNA, snoRNA has been also identified as differentially
expressed in some diseases, including MS [12,13].
The vast majority of the studies aimed at the identifi-
cation of relevant miRNAs for a disease or a condition
using miRNA expression data, have done so by analyzing
differential expression. However, the involvement of
sncRNAs in a disease or a specific condition can be
studied not only through the analysis of differential ex-
pression, but also through the characterization of the al-
terations of the sncRNA – mRNA regulatory network.
The description of the alterations this network presents
in association to a certain phenotype can lead to the
identification of the most relevant sncRNAs driving
these alterations and provide additional information to
determine the sncRNAs that could have a central role in
the disease.
The construction of miRNA – mRNA networks has
already been used for several purposes such as shedding
light on the role of miRNAs in cancer [14-16], studying
the effect of infections on host miRNA – mRNA net-
works [17,18] or analyzing the rewiring of the transcrip-
tional regulation network in the allogeneic response of
T cells [19]. However, in most of these works, miRNA –
mRNA networks (built from expression data for both
miRNAs and mRNAs in some works, using computa-
tional miRNA target-prediction algorithms in others and
applying both approaches in some few cases) were used
to provide a regulatory context to differential expression
analysis results by either building the networks only for
the differentially expressed miRNAs/mRNAs or by map-
ping the fold-changes obtained for those transcripts in a
global network. From the works referenced above, only
one [16] used differential network analysis to describe
the effect of cancer in miRNA – mRNA networks, show-
ing that, although the structure of the network was not
altered, the strength of the connections changed in can-
cer patients when compared to healthy controls.
In the present work, we have used a differential net-
work analysis approach to, on one hand, understand the
alterations that the diseased status of MS produces in
the ncRNA – mRNA coexpression network and, on the
other hand, identify the most relevant ncRNAs for MS
physiopathology. ncRNA – mRNA coexpression net-
works have been constructed from both ncRNA (specif-
ically miRNAs, snoRNAs and sdRNAs) and mRNA
large-scale expression data obtained from patients in re-
lapse, the same patients in remission and healthy con-
trols. Condition-specific (relapse, remission and healthy)
networks have been built and compared to identify the
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aid the identification of potential therapeutic targets
among the selected ncRNAs.
Methods
Design of the study
The gene expression data for the present study was col-
lected from two studies performed in parallel in our la-
boratory (Figure 1). In one of them (from now on the
GEXEM study) the whole genome mRNA expression
analysis of 22 MS patients in remission and relapse and
22 age and sex-matched healthy controls was performed
[20]. In the other study (from now on the miRNEM
study) the expression of selected ncRNAs was analyzed
in the same samples. In total, after the quality control,
65 samples, obtained from 22 patients in relapse and re-
mission and 21 healthy controls (Additional file 1: Table
S1), had both mRNA and ncRNA expression data. The
mRNA and ncRNA expression data from those 65 sam-
ples and the results of the differential expression analysis
of the miRNEM study were used in the present work.
Subjects and sample collection
All MS patients were diagnosed with Relapsing-Remitting
Multiple Sclerosis according to McDonald criteria [21].Figure 1 Design of the study. The gene expression data come from two
Large scale mRNA expression and miRNA expression have been measured
the Human Gene 1.0 ST and the miRNA 1.0 arrays by Affymetrix. The remo
genes have yielded a matrix with gene expression data from 65 samples a
computed between all pairs of genes and, after thresholding (through the
the correlations below a threshold │R│), the resulting network has been viTwo peripheral blood samples were collected from each
MS patient, one sample in relapse and one in remission;
only one sample was collected for each control subject.
Relapse was defined as the development of new or recur-
rent neurological symptoms not associated with fever or
infection lasting for at least 24 hours and accompanied by
new neurological sign, following a period of symptomatic
stability of 30 days [22]. Peripheral blood of patients and
healthy controls was obtained at the Neurology Depart-
ment of Donostia University Hospital. Blood extraction
was performed in the early morning for controls and re-
mission samples and at arrival of the patient for relapse
samples. In this last case, blood extraction always pre-
ceded the administration of steroids for relapses. RNA
extraction was carried out no more than 2 hours after the
blood was collected and during this time blood samples
were kept at 4°C. In all the cases, 10 ml of blood were col-
lected in EDTA tubes by venipuncture. All the procedures
have been approved by the hospital’s ethic committee
(Comité ético de investigación Clínica del area sanitaria
de Gipuzkoa/Ethic committee of Clinical research in the
Health area of Gipuzkoa). Written informed consent was
received from participants prior their inclusion in the
study, where they authorized the publication of their age,
sex and clinical details in scientific articles and meetings.studies performed in parallel in the laboratory: GEXEM and miRNEM.
on RNA isolated from peripheral blood leukocytes using, respectively,
val of some samples for quality control issues and the filtering of
nd 7564 genes (1113 ncRNAs and 6451 mRNAs). Pearson’s R has been
elimination all mRNA – mRNA and ncRNA – ncRNA correlations and
sualized in Cytoscape.
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RNA extraction from leukocytes was performed using
the LeucoLOCK™ Total RNA Isolation System by
Ambion with the alternative protocol to recover Total
RNA. RNA samples were aliquoted and stored at −80°C
for later use. Samples were extracted and stored at the
Donostia – San Sebastián node of the Basque Biobank
(www.biobancovasco.com). Before the gene expression
analysis, RNA integrity was checked with the Agilent
RNA 6000 Nano kit and the samples with an RNA
Integrity value (RIN) above 6 were accepted to be fur-
ther processed.
The GEXEM study
Whole genome gene expression of the samples was mea-
sured by the Human Gene 1.0 ST Affymetrix microarray.
300 ng of total RNA were used for microarray analysis
following the manufacturer’s instructions. Both the WT
Expression Kit by Ambion and the GeneChip Hybri-
dization Wash and Stain kit by Affymetrix were used
in the process. Briefly, during the three-day protocol,
complementary single-strand DNA was synthesized from
RNA, to be later fragmented, labeled and hybridized
during 16 hours. The hybridized microarrays were washed
and stained in a GeneChip Fluidics Station 450 and
scanned in a GeneChip 7G Scanner afterwards.
The data of the .cel files were normalized with the
Robust Multichip Average (RMA) in the Expression
Console software by Affymetrix. As multiple-testing cor-
rection makes the group-wise comparisons more stringent
as more genes are included in the analysis, we filtered
the data to remove the least informative genes using the
BRB-Array Tools software [BRB-ArrayTools Development
Team, version 4.2.1] implemented in Microsoft Excel
[Microsoft Corporation, Microsoft Office Professional
Edition 2003]. The genes with a 90th percentile value
smaller than 55.7 (the mean intensity of the negative con-
trol probes) were removed and 6451 probesets were left
for the subsequent analysis.
The miRNEM study
The selected ncRNA expression analysis was done with
the GeneChip miRNA array v1 by Affymetrix. 500 ng of
total RNA were used for microarray analysis following
the manufacturer’s instructions. The quality control,
summarization and normalization of ncRNA expression
data was done with the miRNA QC Tool v.1.0.33.0 soft-
ware by Affymetrix. Whether the detection of the ex-
pression for each probe was significant or not was
determined by comparing them against the anti-genomic
probes present in the array using a Wilcoxon test for the
miRNA probesets and the Affymetrix Power Tool for
the rest (snoRNA and sdRNA probesets). Afterwards,
background correction and quantile-based normalizationof the data were done. The summarization of the data
was performed with the RMA algorithm. Finally, in
order to reduce the dimensionality of the dataset, the
non-human probes present in the array and the probes
not detected in any of the samples were filtered out.
After these two filtering steps, 1113 probes were left for
the subsequent analysis.
The differential expression analysis was performed
with the MEV 4.7.2 software [23,24]. The dataset was
subdivided based on treatment and two comparisons
were done for each subgroup: relapse vs. remission and
remission vs. controls. For the identification of the dif-
ferentially expressed ncRNAs, the Rank Products algo-
rithm was used [25]. This procedure resulted in a 25
probe-list with ncRNAs altered in relapse (vs. remission)
and a 53 probe-list with ncRNAs altered in remission
(vs. controls).
Coexpression network analysis
Before the construction of gene expression correlation
matrices, and in order to make the data obtained from
each study comparable, a standardization of the data
was done. For that, z-scores were calculated for all gene
expression values (including mRNA and ncRNA data)
and those were used for the subsequent coexpression
analysis. Coexpression matrices were created in Pylab by
computing pairwise Pearson’s R between all the gene-
pairs. From a gene expression dataset with x genes and y
samples, x2 pairwise Pearson’s R correlations were com-
puted using, in each case, two expression vectors with
length y. In each of the different coexpression analyses,
the threshold to cut the matrix was established consider-
ing the length of the vectors used in the computation of
R, i.e. the number of expression values for each gene (y).
The resulting matrix was transformed into a column-
format network with the following structure: gene 1 –
correlation value – gene 2. The visualization and analysis
of the resulting networks was performed in Cytoscape
3.0.1 [26].
Results
Global network
In order to gain insight into the general structure of the
ncRNA – mRNA network, a global coexpression net-
work has been inferred from the gene expression data
from the 65 samples and the 7564 transcripts (6451
mRNAs and 1113 ncRNAs). Under the assumption that
miRNAs downregulate mRNA expression by either
blocking translation or promoting degradation and con-
sidering the evidence that snoRNAs, through their role
as sdRNA precursors, might exert a similar effect on
mRNA expression, only the negative correlation values
between the selected ncRNAs and mRNAs were se-
lected. Thus, taking into account the length of the
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samples (N) = 65), the matrix obtained in the correlation
analysis was cut at Pearson’s R < −0.42 (p = 0.0005) and
all the mRNA – mRNA and ncRNA – ncRNA correla-
tions (the intra-array correlations) were removed. The
resulting network (wired by negative ncRNA – mRNA
correlations only) presents one fully connected compo-
nent composed of 4101 nodes (3489 mRNAs (54.08% of
all mRNAs) and 612 ncRNAs (54.99% of all ncRNAs))
and 29600 negative correlations (ranging from −0.42
to −0.7) (Figure 2A). In contrast, the coexpression net-
work wired by positive ncRNA – mRNA correlations
(Pearson’s R > 0.42) is composed by 6069 nodes and
56461 edges (Additional file 1: Figure S1).
The node-degree distribution of the global coexpres-
sion network fits a negative power law (y = 889.08 x-1.26;
where y is the number of nodes and x is the degree)
indicating a scale-free topology (Figure 2B). Besides, a
combined centrality measure has been computed for allFigure 2 Global ncRNA – mRNA coexpression network. The global network
correlations below −0.42. The node degree distribution is represented in a log
nodes (ncRNAs all of them) with a combined centrality value (betweeness ce
neighbors form the core subnetwork (D).nodes by multiplying the outdegree (the number of
edges that originate from a node) and the betweeness
centrality (the fraction of all shortest paths of the net-
work that pass through that particular node). This com-
bined centrality has been computed with the aim of
obtaining a parameter that reflects both the strength of
the effect of each ncRNA (how many genes it targets)
and its importance on the global connectivity of the net-
work. The nodes with a combined centrality above 8.6
(97.5th percentile) are 15 ncRNAs (6 snoRNAs and 9
miRNAs) (Figure 2C) and, along with their first neigh-
bors (2176 genes), form the core of the global network
(Figure 2D).
Status-specific networks
With the aim of testing the effect that disease status
(patients in relapse, patients in remission or healthy con-
trols) exerts on the global ncRNA – mRNA coexpression
pattern, status-specific networks were created. As for thepresents an only fully-connected component (A) wired by ncRNA – mRNA
arithmic scale in both axes and fits a negative power law (B). The 15
ntrality * outdegree) above 8.6 (percentile 0.975) (C) and their first
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tions were included but, in this case, accordingly to the
lower length of the vectors used in the computation
(i.e. smaller sample size; 22 for relapse and remission and
21 for controls), more stringent Pearson’s R cutoff thresh-
olds were used (R < − 0.537 for relapse and remission;
R < − 0.549 for controls; p = 0.01 in all cases).
To check whether the disease status has any influence
on the topological characteristics of the ncRNA –
mRNA network, several parameters describing network-
topology have been calculated and plotted (Figure 3).
Three basic descriptors, the total size of the network
(number of nodes + edges, Figure 3A), the average
shortest path-length (Figure 3B) and the mean degree
(Figure 3C), suggest that, regarding topology, the net-
works inferred from relapse and remission samplesFigure 3 Status-specific ncRNA-mRNA network comparison based on
(A), the average shortest-path length (B) and the average degree (C) have
three networks follows a negative power law (D), indicating a scale-free to
for relapse, −1.431 for remission and −1.484 for controls). The frequency di
been plotted (E). Finally, the similarity of the three networks has been estimat
accounting, respectively, for 88.76% and 11.07% of the variability have been p
parameters have been used: number of connected components, network centr
and the argument of the power law fitting the node degree distribution.present a higher similarity than that obtained from con-
trol samples. In general, the controls’ network is larger
(includes more nodes and edges) and shows a remarkably
higher connectivity (higher mean degree). Nevertheless,
despite presenting a higher connectivity, the efficiency for
transmission of information (there is transmission of
information through an edge that links A and B, if the be-
havior of variable A (the expression of a miRNA) in-
fluences the behavior of variable B (the expression of an
mRNA) and/or vice versa) is not higher in the controls’
network as the three graphs show a very similar average
shortest path-length.
On the other hand, as that of the global network, the
frequency distribution of the three status-specific net-
works fits a negative power law (Figure 3D), indicating a
scale-free topology. The correlation values of the powerparameters describing network topology. The size of the network
been calculated for each network. The node degree distribution of the
pology and the arguments are very similar in the three cases (−1.439
stributions of the shortest path-length of the three networks have also
ed with a Principal Component Analysis (PCA). The first two components
lotted (F). For the PCA, the values of the following network descriptor
alization, characteristic path-length, average degree, network heterogeneity
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for relapse, 0.842 for remission and 0.813 for controls)
but remain statistically significant (p < 10−8 in all cases).
The argument is similar for the three distributions
(−1.439 for relapse, −1.431 for remission and −1.484 for
controls), which suggests that the proportion of hubs
and poorly connected nodes is similar in the three net-
works. The distribution of the shortest path-length bet-
ween all pairs of nodes (Figure 3E) is also very similar
for the three graphs. However, for the two parameters,
the relapse and remission distributions seem to be more
similar and the one obtained for the controls’ network
appears to be the outlier.
In order to get a more accurate idea of the similarity/
dissimilarity of the three networks, a Principal Compo-
nent Analysis (PCA) has been performed using the
values obtained for several topology descriptors: number
of connected components, network centralization, aver-
age path-length, mean degree, network heterogeneity
and the argument of the power law. The networks have
been plotted based on their values for the two principal
components of the PCA analysis, which, respectively, ac-
count for 88.76% and 11.07% of the variability (Figure 3F).
The results of the PCA indicate that, as suggested by the
simple topology descriptors and the distributions of the
node-degree and the shortest path-length, the controls’
network is the outlier and, from the point of view of
similarity/dissimilarity of network topology, the relapse
and remission networks are closer to each other; an un-
surprising result considering that the gene expression data
for the relapse and remission networks come from the
very same patients, while the data for the controls’ net-
work comes from a different population.
Nevertheless, the node degree and shortest path-
length distributions of the three networks seem to be
very similar, a notion that is supported by the fact that
the correlations between the node-degree distributions
lie above 0.9998 (p < 10−8 in all cases) and those between
the shortest path-length distributions range from 0.9881
to 0.9997 (p < 10−8 in all cases).
Thus, we hypothesized that, if the topology of the three
status-specific networks has similar features, the lists of
the top ncRNAs/mRNAs playing a central role in each of
the three networks should also overlap. However, from
the 65 unique ncRNAs with a combined centrality in the
top 2.5% (97.5th percentile), only six (hsa-miR-181a, hsa-
miR-423-3p, hsa-miR-1225-5p, hsa-miR-1268, SNORA40
and SNORD23) appear in two lists (Table 1). The rest of
the ncRNAs (59) play a central role in only one of the net-
works. This fact suggests that despite the high similarity
of the architecture of the status-specific networks, the spe-
cific genes playing central roles are different and, thus, dif-
ferent members of the transcriptome are involved in the
core ncRNA – mRNA network in different conditions.Differential networks
Considering that despite the high similarity in network
topology between the status-specific networks the key
ncRNAs seem to be different in each of the conditions,
we decided to perform node to node and edge to edge
comparisons between the networks with the aim of
identifying which part of each is network is shared by
the others.
The results of the node to node and edge to edge com-
parisons between the networks show that, whereas the
three networks share a high proportion of their nodes
(Figure 4A and C), they share very few edges (Figure 4B
and C). This suggests that, even though the players of
the coexpression network and the general topology are
maintained between the different disease statuses, the
relations between genes change in most of the cases.
Based on that, it seems that a massive rewiring of the
ncRNA – mRNA correlation network happens between
conditions, which, although has little impact in topo-
logical features, provokes a big change in which ncRNAs
play a central role in each of the networks (Table 1).
On the other hand, from the 150079 unique edges that
appear in any of the three networks, only 201 (0.13%)
appear in the three networks (Figure 4B). The largest
component of the network wired by these 201 edges, is a
53 node/56 edge network (Figure 4D) that represents a
status-independent core network that appears in peri-
pheral blood leukocytes irrespective of disease status. As
it could be expected, six of the ten ncRNAs that provide
the backbone for this network have appeared as being
central for network topology in previous lists: hsa-miR-
331-5p, hsa-miR-1246, SNORA5C, SNORA40, SNORD23
and SNORD62 (Figure 2C and Table 1).
Finally, a network has been constructed with the 2307
edges shared by the relapse and remission networks, but
not the controls’ network (Figure 4B), with the aim of
identifying a disease-specific network that could guide the
detection of ncRNAs with potential to be used as thera-
peutic targets. The largest component of the resulting net-
work is composed by 401 nodes and 742 edges (Figure 5).
Therapeutic target candidate selection
From the ncRNAs that appear in this last network, the
ones that in a previous differential expression analysis
(miRNEM study, results not published) were found to
be as differentially expressed in relapse (vs. remission) or
in remission (vs. controls), have been selected as po-
tential candidates for therapeutic intervention (Table 2).
The rationale behind this is that the ncRNA whose ex-
pression has been found to be significantly altered in MS
(in relapse or remission, or both) and that is part of a
disease-specific network must presumably have a rele-
vant role in the physiopathology of the disease and, thus,
it can be a good therapeutic target candidate.
Table 1 Lists of top ncRNAs for each status-specific network
Relapse Remission Controls
ncRNA Combined
centrality
ncRNA Combined
centrality
ncRNA Combined
centrality
hsa-miR-671-3p 53.70 hsa-miR-181a 72.64 hsa-miR-1246 17.56
hsa-miR-744 26.81 SNORA16 25.17 hsa-miR-181a 16.42
hsa-miR-99b* 15.75 hsa-miR-768-5p 20.27 SNORD116-8 11.50
SNORD23 10.92 SNORD16 17.49 SNORA42 7.19
SNORA58 10.76 hsa-miR-574-5p 13.93 hsa-miR-339-5p 7.08
hsa-miR-331-5p 10.25 SNORD57 13.03 SNORD1C 5.52
SNORA41 7.91 SNORD55 10.25 SNORD4B 4.72
hsa-miR-425 7.45 SNORD42A 8.01 SNORD60 4.55
hsa-miR-1224-5p 6.89 SNORD68 7.56 SNORD80 4.33
hsa-miR-1228 6.79 hsa-miR-423-3p 7.41 hsa-miR-671-5p 4.26
hsa-miR-1225-5p 5.07 hsa-miR-1225-5p 5.29 hsa-miR-708 4.09
hsa-miR-423-3p 4.99 hsa-miR-130b 5.29 hsa-miR-484 4.03
SNORA31 4.98 hsa-miR-532-5p 4.81 SNORD18C 4.02
SNORA51 4.91 SNORA6 4.81 SNORD28 4.00
SNORD9 3.84 hsa-miR-194* 4.74 SNORD87 3.84
SNORD115-8 3.75 SNORD116-2 4.51 hsa-miR-342-3p 3.75
SNORD118 3.74 hsa-miR-154* 4.27 hsa-miR-593 3.14
hsa-miR-1268 3.48 hsa-miR-1306 4.05 SNORA40 3.07
hsa-miR-30b 3.34 SNORD116 3.56 SNORD13 2.81
SNORA5C 3.03 hsa-miR-185 3.53 SNORD29 2.80
SNORA40 2.74 hsa-miR-195* 3.48 SNORD44 2.75
SNORA2 2.73 hsa-miR-1268 2.73 SCARNA23 2.68
hsa-miR-491-5p 2.70 hsa-miR-346 2.62 hsa-miR-191 2.59
hsa-miR-15b 2.50
SNORD23 2.43
The top 2.5% (97.5th percentile) of the genes with the highest combined centrality (betweeness centrality * outdegree) are shown. The six genes that appear in
two lists (hsa-miR-181a, hsa-miR-423-3p, hsa-miR-1225-5p, hsa-miR-1268, SNORA40 and SNORD23) are in bold.
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didates with potential to be used as therapeutic targets.
However, it must be taken into account that two of
them, SNORD62 and hsa-miR-1246, have been revealed
to have a key role in the global network and are part of
the core status-independent network, suggesting that
their manipulation would have a large impact in the
transcriptome of in peripheral blood leukocytes and,
thus, a therapeutic approach based on their manipula-
tion could produce many effects beyond the desired
ones. Besides, SNORA40 has also appeared both in the
controls’ network as an important connector and in the
core condition-independent network. However, it does
not hold a prime position among the top ncRNAs of the
controls’ network (18th highest combined centrality) and its
connectivity is very low in the core network (outdegree = 2).Thus, although it must be manipulated with care, we still
consider SNORA40 one of the best candidates for a hypo-
thetical therapeutic intervention.
Discussion
With the aim of studying the coexpression relations bet-
ween selected ncRNAs (miRNAs, snoRNAs and sdRNAs)
and mRNAs and the effect that the diseased-state of mul-
tiple sclerosis exerts on those relations, ncRNA – mRNA
negative correlation networks have been built from both
whole genome mRNA and ncRNA expression data ob-
tained from MS patients in relapse and remission and
healthy controls. Condition-specific networks (relapse, re-
mission and healthy controls’ networks) have been built
and compared in order to identify the parts of the system
most perturbed by the disease. Finally, the most central
Figure 4 Node to node and edge to edge comparisons of the ncRNA – mRNA networks obtained from the relapse, remission and
control samples. The venn diagrams show the number of nodes (A) and edges (B) shared by the three networks. The proportion of shared
nodes/edges between status-specific networks is also shown (C). Finally, the largest component (53 nodes/56 edges) of the network wired by the
201 edges that appear in all three networks is shown (D).
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with the aim of obtaining a list of candidate therapeutic
targets.
The study has been performed in peripheral blood leu-
kocytes isolated from patients with a disease where the
most affected system is the central nervous system, what
might look contradictory. It needs to be kept in mind,
however, that a fraction of the immune cells that execute
the aberrant immunological attack against the myelin
migrate from peripheral blood to the CNS through a
disrupted blood–brain barrier [27]. Besides, most of the
disease-modifying treatments used today against RRMS
are based on immunomodulatory drugs that target the
immune cells of peripheral blood and that, although not
capable of completely stopping the progression of the
disease, produce a big decrease in the relapse rate, poin-
ting at an important pathophysiological function in MS
for those cells [28]. Evidence suggests that several typesof leukocytes (mainly B cells, Th17 cells, Th1 cells and
macrophages) participate in the immunological attack
that produces the lesions [29].
Scale-free topology
In accordance to previous large-scale coexpression stu-
dies, the node-degree distribution of the ncRNA –
mRNA networks we have built for the present study
follows a negative power law in all cases, suggesting a
scale-free topology. After the appearance of the first
large-scale coexpression networks in the early 2000s,
their scale-free topology was described soon. Apart from
isolated exceptions where a negative exponential-law
was found to be a better fit [30], the node-degree distri-
butions of most large-scale coexpression networks built
for organisms as different as Saccharomyces cerevisiae
[31,32], mice [33] and human [33-35] and diseased states
like gastric cancer [36], have been found to follow a
Figure 5 Largest component (401 nodes/742 edges) of the network built from the 2307 edges shared by the relapse and remission
networks but not the controls’ network.
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power-law has been shown to lie between −3 and −2 for
metabolic and protein interaction networks [36], it has
been demonstrated that it lies between −2 and −1 for
coexpression networks [31,34,36], which coincides with
the values we have obtained (from −1.484 to −1.260).
In contrast, the coexpression network we created for a
differentially expressed gene set in a previous study did
not show a scale-free topology [20]. It has to be kept in
mind, however, that the scale-free topology property of
coexpression networks appears when we analyze the
whole system or a substantial part of it and that we may
not observe this property when constructing small net-
works using, for example, only the genes found to be
deregulated in a differential expression analysis. The
scale-free property may be lost if the part of the system
we are studying is small enough. Besides, the genes
identified as upregulated/downregulated in a differentialexpression analysis tend to form tightly coregulated
groups and give rise to extremely clustered and non-
scale-free coexpression networks.
Massive rewiring between conditions
As we have commented previously, it has been suggested
that, to take profit of all the power of network analysis in
biological studies, we need to take into account that
biological networks are not constant across organisms,
tissues, physiological states etc., but suffer substantial
changes between different conditions [37]. A recent study
has shown that the addition of a DNA damaging agent
(methyl-methane-sulfonate (MMS)) produces a massive
rewiring of the genetic functional interaction network in
yeast [38]. The authors created genetic networks based on
functional interactions between the 418 genes of yeast for
both the untreated and the MMS-treated conditions and
observed that from the 3126 unique interactions present
Table 2 List of potential therapeutic ncRNA targets
selected from the disease-specific network and that, in a
previous analysis (results not published), were identified
as differentially expressed genes either in relapse
(vs. remission), in remission (vs. controls) or in both
conditions
ncRNA DEG_REL DEG_REM Outdegree
SNORD62 yes no 39
SNORA40* yes yes 24
hsa-miR-1246 yes yes 22
hsa-miR-20b yes no 17
hsa-miR-331-5p yes no 15
hsa-miR-1224-5p yes no 14
SNORA15 yes no 7
hsa-miR-660 no yes 7
SNORA24 yes no 6
hsa-miR-21 no yes 4
hsa-miR-26b yes yes 2
hsa-miR-18b yes yes 2
hsa-let-7f no yes 2
SNORA70 yes no 2
hsa-miR-210 yes yes 2
hsa-miR-1202 yes no 2
hsa-miR-192 no yes 1
hsa-miR-98 yes no 1
DEG_REL: differentially expressed gene in relapse; DEG_REM: differentially
expressed gene in remission. The ncRNAs that have previously appeared as
key connectors in the global network and/or the controls’ network and/or are
part of status-independent network are underlined. SNORA40 (marked*) is a
good therapeutic target candidate that must be manipulated with care.
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specific, demonstrating that the sole addition of a DNA-
damaging chemical agent produces a massive rewiring of
the network.
Besides, one of the major goals of systems biomedicine
is the identification of specific gene-regulatory networks
that are dysfunctional in a given diseased state. Although
we are not capable of performing proper differential
gene regulatory network analyses yet, some steps in this
direction have been taken such as, for example, the
identification of differential coexpression networks [39].
As for the genetic functional interaction network created
in yeast, some evidence suggests that coexpression net-
works also undergo massive rewiring between different
conditions. For example, it has been demonstrated that
when comparing large-scale coexpression networks cre-
ated for mice and humans, although the architecture of
the networks is very similar, a high level of divergence
exits at the local level, as less than 10% of all unique
connections are shared by the networks from both
species [35].We observe a similar phenomenon in the condition-
specific (relapse-, remission- and control-specific) ncRNA –
mRNA coexpression networks we have created for the
differential network analysis. Although the topological fea-
tures of the three networks are practically identical, like in
the mouse/human example, a very low fraction of edges
or connections appear in more than one network. From
the 150079 unique connections present in any of the three
networks, only 201 (0.13%) are shared by the three graphs
and the fraction of edges shared by any pair of networks
lies between 1.32% and 2.81%. These results indicate that
the two diseased-states of multiple sclerosis, the relapse
and the remission, have a strong effect on the coexpres-
sion relations between the selected ncRNAs and mRNAs
and produce a massive rewiring of the ncRNA – mRNA
network. It seems that the topological features of coex-
pression networks are held to constrains that are constant
across species, organisms, tissues and physiological-states
but, inside the limits of network-topology, transcriptomic
networks have great flexibility to respond by changing in-
teractions between genes.
snoRNAs in gene silencing
After the first characterizations of rRNA-bound small
nucleolar RNAs in the mid-70s [40], the two main
snoRNA types that have been characterized, the H/ACA
box and C/D box snoRNAs, have been widely con-
sidered to be involved in an only function, the guidance
of post-transcriptional modifications of rRNA and other
target-RNAs performed by the snoRNP complexes.
However, our results suggest that many snoRNAs may
have a relevant role in post-transcriptional regulation of
gene expression, as revealed by the fact that many of
them present a high number of links to mRNAs and
hold central positions in the several ncRNA – mRNA
coexpression networks we created. This apparent wide-
spread function of snoRNAs in gene silencing cannot be
explained by their well-established involvement in the
splicing machinery and in rRNA modification.
Nevertheless, in an immunoprecipitation followed by
deep-sequencing experiment on RNAs associated to Ago1
and Ago2 (argonaute proteins of the gene-silencing effector
complexes), Ender and collegues found evidence of small
non-coding RNAs derived from SNORA45 (sdRNAs),
whose processing happens in a drosha-independent,
dicer-dependent manner [11]. They predicted CDC2L6 as
a potential target for the sdRNA and found evidence for
snoRNA-derived RNAs with miRNA-like processing sig-
natures and a potential role in post-transcriptional gene
silencing for 7 additional snoRNAs, [11].
That discovery opened the possibility of snoRNAs
having, apart from their involvement in RNA modifica-
tion guidance, an additional function in gene silencing
through their role as precursors for sdRNAs, also called
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plored the potential role of snoRNAs in miRNA-like
small RNA production and the evolutionary/molecular
relationships between snoRNAs and miRNAs. More
work has been done in the direction set by Ender et al.,
and additional snoRNA-derived RNAs have been identi-
fied by deep sequencing and their target-gene silencing
functions have been experimentally validated in many
cases [42]. For example, Scott et al., in a completely
computational approach, tested whether the precursors
of known miRNAs show any SNORA-like (H/ACA box
snoRNA) features and found evidence of at least 20
known miRNA precursors having sequence/confor-
mational similarities with SNORAs. They also observed
that the genomic regions surrounding these SNORA-
like miRNA precursors resemble the regions around
snoRNA retrotransposons, suggesting a close evolution-
ary relationship between SNORAs and miRNAs [43].
Similar findings have been made when applying this ap-
proach to C/D box snoRNAs [44]. It has recently been
proposed a model where the RNA species we include in
the snoRNA and miRNA families would form a
spectrum from classical snoRNAs to prototypical miR-
NAs: classical snoRNAs ↔ snoRNAs with miRNA-like
features ↔ dual function sno-miRNAs ↔ miRNAs with
snoRNA-like features ↔ prototypical miRNAs [41].
It is clear, thus, that the precursors of many known
miRNAs have snoRNA-like features and that many
snoRNAs present miRNA precursor features and are in-
volved in miRNA or miRNA-like RNA production in a
Drosha-independent Dicer-dependent manner. This in-
dicates that snoRNAs probably have a relevant role in
the post-transcriptional downregulation of gene expres-
sion through the involvement of their product sdRNAs
(snoRNA-derived RNAs or sno-miRNAs) in the gene
silencing effector complexes.
However, our results suggest that this sdRNA-precursor
and gene silencing role of snoRNAs is not a rare event but
a widespread phenomenon affecting a big fraction of
snoRNAs. From the 169 snoRNAs (87 H/ACA box and
82 C/D box snoRNAs) left for subsequent analysis after
the initial filtering of the miRNA array data, 118 (69.82%)
appear in the global network as negatively correlated with
mRNAs. This result concurs with previous estimations of
around 60% of human snoRNAs showing evidence of
being precursors of highly conserved sdRNAs with a po-
tential miRNA-like function [45].
A consistent central role for hsa-miR-1246
Our results point at hsa-miR-1246 as having a consistent
central position in the ncRNA – mRNA coexpression
network of peripheral blood leukocytes, as it appears to
be one of the key connectors in the global network,
the controls’ network and the core status-independentnetwork. These results suggest that miR-1246 may hold
a central position in the gene regulatory network of
leukocytes.
However, as it happens with many miRNAs, the role
of miR-1246 has mostly been studied in relation to
diseases, especially cancer. It has been shown that miR-
1246 is one of the mediators of the pro-apoptotic activity
of p53 and its analogs p63 and p73. The transcription of
miR-1246 is activated by these genes and miR-1246, in turn,
downregulates DYRK1A, a Down syndrome-associated
protein kinase, establishing a link between cancer and
Down syndrome [46,47]. This miRNA has also been
found to be upregulated in hepatoma cells upon infec-
tion with the hepatitis C virus [48]. Apart from cancer,
miR-1246 has been shown to be involved in the regula-
tion of chloride transport in epithelial cells by targeting
CFTR and SLC12A2 [49] and in the regulatory pheno-
type of T cells [50].
Interestingly, miR-1246 has been identified in extra-
cellular vesicles (microvesicles, microparticles and exo-
somes) derived from a wide range of cell types and cell
lines. This miRNA has been found in microparticles
derived from platelets [51], in exosomes released by
malignant epithelial cells [52] and in microparticles and
microvescicles derived from a variety of cell lines like
THP-1 (a monocytic cell-line derived from an acute
monocytic leukemia patient) and HUVEC (a cell line
derived from the endothelium of the veins of the
umbilical cord) [51].
Top therapeutic target candidate selection
The selection of potential therapeutic target ncRNAs
has been done based on the premise that if a ncRNA
appears in the multiple sclerosis-specific coexpression
network and, in addition, has been shown to be differen-
tially expressed in any or both of the phases of the dis-
ease (relapse and remission) (unpublished results from
the miRNEM study) it must have a relevant role in the
physiopathology of the disease.
Among the selected ncRNAs, the best candidates for a
therapeutic intervention are those with a high outdegree
in the disease-specific network and, thus, SNORA40,
miR-20b, miR-331-5p and miR-1224-5p appear to be the
most prominent candidates. Since the revival of network
analysis techniques for the modeling of biological sys-
tems, several groups have found evidence that the con-
nectivity of a gene in a biological network is a good
prediction of the essentiality of the gene for the orga-
nism and the probability of its removal having lethal
consequences. In 2001, Jeong et al., demonstrated that
the phenotypic consequence of a single gene deletion in
Sacchromyces cerevisiae is affected to a large extent by
the topological position of its protein product in the
complex hierarchical web of molecule interactions [53].
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the cell are the most important for its function”. Since
then, this correlation between the centrality of a gene in
a gene-network and its essentiality has been observed in
several types of biological networks and organisms. It
has been shown that the proteins with a central position
in the protein interaction networks of yeast (S. cerevi-
siae), worm (C. elegans) and fly (D. melanogaster) evolve
slowly and are more likely to be essential for survival
[54] and similar observations have been made on a
C. elegans genetic network constructed by integrating
coexpression at the RNA level, interactions at the protein
level and co-citations between genes in the literature [55].
In front of all this evidence, thus, it seems evident that the
connectivity of a gene in a genetic network (whether it is a
protein interaction network, a gene functional network or
a coexpression network) is strongly correlated with its es-
sentiality and and this is why we use centrality measures
to interpret the importance that miRNAs and snoRNAs
may have both for normal physiology (in the global and
controls’ networks) and for multiple sclerosis pathophy-
siology (in the relapse and remission networks and, spe-
cially, in the disease-specific network).
Besides, several works have demonstrated that the
removal of miRNA genes has, in some cases, a strong effect
on the phenotype of mice (reviewed in [56]). Although the
creation of knockout mice for some miRNAs does not pro-
duce any apparent changes on phenotype (as is the case for
miR-106a-363, miR-208b, miR-499 and miR-140, among
others), the removal of other miRNAs has been shown to
have a strong effect on the phenotype of the knockout
mouse in question. For example, the miR-1-2 knockout
mouse presents a mortality of 50% with cardiac defects;
the removal of miR-155 produces an impairment of T-cell
and B-cell dependent immunity; and the knockout mouse
for the islet-expressed miR-375 suffers hyperglycemia.
Taking into account that, on one hand, the centrality of
genes in molecular networks is strongly correlated to their
essentiality and, on the other hand, that the removal of
non-coding genes such as miRNAs can exert a strong ef-
fect on the phenotype of a higher organism such as mice,
we think that SNORA40, miR-20b, miR-331-5p and miR-
1124-5p are the best candidates to be considered as thera-
peutic target ncRNAs in MS. Following the same logic,
SNORD62 and miR-1246 should not be manipulated in a
hypothetical therapeutic strategy as they seem to have a
consistent central role in conditions of physiological
normality, as revealed by their central positions both in
the global and the controls’ ncRNA – mRNA coexpres-
sion networks.
SNORA40
Based on its central role in the disease-specific network
and the differential expression detected for it in themiRNEM study, the ncRNA that, above all the rest,
seems to be the most prominent candidate for a hypo-
thetical therapeutic intervention is SNORA40. This is
the ncRNA that, apart from SNORD62 (which also has
central roles in the global and controls’ networks), shows
the highest outdegree in the disease-specific network. It
is true that it appears in the list of top connectors for
the controls’ network and is also part of the core status-
independent network. Nevertheless, it does not hold a
prime position among the top connectors of the controls’
network and its connectivity is very low in the core
network. Besides, it has been identified as deregulated
both in relapse and remission, showing a fold-change of
9.21 in relapses of female patients (unpublished data from
miRNEM). Thus, we consider that, although it must be
manipulated with care, SNORA40 is a good candidate
target for a hypothetical therapeutic intervention.
This H/ACA box small-nucleolar RNA has been shown
to be involved in cancer and senescence. SNORA40 has
been seen to be overexpressed in plasma cells (antibody-
secreting B cells) from patients with multiple myeloma of
the TC1 subgroup when compared to those from healthy
controls [57]. In another work aimed at the characte-
rization of the molecular mechanisms of senescence, a
RNA-seq experiment was performed on RNA isolated
from the cartilage of young (<4 years) and elder (<15 years)
horses and SNORA40 was found to be overexpressed in
the cartilage of the elder donors [58].
Even more interestingly, alterations in the expression of
this snoRNA have been observed in relation to normal
and aberrant immunological responses. It has recently
been studied the alteration of the transcriptional profile of
NK92 cells (a cell line with characteristics of natural killer
cells) when co-cultured with red blood cells infected with
the malaria agent Plasmodium falciparium in order to
shed light on the molecular mechanisms implicated in the
response of natural killer cells to the infection by this
pathogen. The authors found that SNORA40 was signifi-
cantly overexpressed in the NK92 cells responding to the
infected red blood cells, suggesting that it may have a
relevant role in the natural killer cell response to P. falci-
parium infection [59]. Besides, SNORA40, along with
other snoRNAs and olfactory receptor genes, was found
to be part of a coexpression module composed of genes
upregulated in exacerbations of children with asthma [60].
The results of this last study overlap surprisingly well with
the results we obtained in the GEXEM study [20], as we
identified two coexpression modules composed mainly of
small non-coding RNAs (in females) and olfactory recep-
tors (in males) among the genes upregulated in relapses.
All this evidence suggests that SNORA40 may have a con-
sistent and relevant role in aberrant responses of the im-
mune system such as allergic (asthma) and autoimmune
(multiple sclerosis) responses.
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Our results indicate that the two diseased states of
multiple sclerosis, relapse and remission, have a strong
impact on the organization of the ncRNA – mRNA
coexpression network of the peripheral blood leukocytes,
as we have observed a massive rewiring of the network
between conditions. Besides, the consitent and promi-
nent presence of snoRNAs among the top regulators of
the several networks built in the present work points at
the previously described function at targeted downregu-
lation of gene expression of these ncRNAs as being a
widespread phenomenon. Finally, the combination of
differential expression and differential coexpression
analyses has allowed the identification of miR-20b, miR-
331-5p, miR-1246 and SNORA40 as potential theraputic
targets in multiple sclerosis, SNORA40 being the pro-
mising candidate.
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